Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses
Current seasonal influenza vaccines have reduced immunogenicity and are of suboptimal efficacy in older adults. We have previously shown that the novel candidate vaccine MVA-NP+M1 is able to boost memory T cell responses in adults aged 50-85 years. Preclinical studies have demonstrated that viral ve...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
2014
|
| _version_ | 1797050209571700736 |
|---|---|
| author | Antrobus, R Berthoud, T Mullarkey, C Hoschler, K Coughlan, L Zambon, M Hill, A Gilbert, S |
| author_facet | Antrobus, R Berthoud, T Mullarkey, C Hoschler, K Coughlan, L Zambon, M Hill, A Gilbert, S |
| author_sort | Antrobus, R |
| collection | OXFORD |
| description | Current seasonal influenza vaccines have reduced immunogenicity and are of suboptimal efficacy in older adults. We have previously shown that the novel candidate vaccine MVA-NP+M1 is able to boost memory T cell responses in adults aged 50-85 years. Preclinical studies have demonstrated that viral vectored vaccines can act as adjuvants when coadministered with protein-based vaccines. We have conducted a phase I clinical trial to compare the coadministration of seasonal influenza vaccine and MVA-NP+M1 with seasonal influenza vaccine alone in adults aged 50 years and above. This combination of vaccines was safe and well tolerated. T cell responses to internal influenza proteins were boosted to significantly higher levels in the group receiving MVA-NP+M1 compared with the group receiving seasonal influenza vaccine alone. Rates of seroprotection and seroconversion against the three vaccine strains were similar in both groups; however, there was a significant increase in the geometric mean titer ratio for the H3N2 component of seasonal influenza vaccine in the coadministration group. While some vaccine combinations result in immune interference, the coadministration of MVA-NP+M1 alongside seasonal influenza vaccine is shown here to increase some influenza strain-specific antibody responses and boost memory T cells capable of recognizing a range of influenza A subtypes. © The American Society of Gene and Cell Therapy. |
| first_indexed | 2024-03-06T18:01:47Z |
| format | Journal article |
| id | oxford-uuid:00071d4f-ec6e-43d2-85d7-e4c6a7427843 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T18:01:47Z |
| publishDate | 2014 |
| record_format | dspace |
| spelling | oxford-uuid:00071d4f-ec6e-43d2-85d7-e4c6a74278432022-03-26T08:27:15ZCoadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responsesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:00071d4f-ec6e-43d2-85d7-e4c6a7427843Symplectic Elements at Oxford2014Antrobus, RBerthoud, TMullarkey, CHoschler, KCoughlan, LZambon, MHill, AGilbert, SCurrent seasonal influenza vaccines have reduced immunogenicity and are of suboptimal efficacy in older adults. We have previously shown that the novel candidate vaccine MVA-NP+M1 is able to boost memory T cell responses in adults aged 50-85 years. Preclinical studies have demonstrated that viral vectored vaccines can act as adjuvants when coadministered with protein-based vaccines. We have conducted a phase I clinical trial to compare the coadministration of seasonal influenza vaccine and MVA-NP+M1 with seasonal influenza vaccine alone in adults aged 50 years and above. This combination of vaccines was safe and well tolerated. T cell responses to internal influenza proteins were boosted to significantly higher levels in the group receiving MVA-NP+M1 compared with the group receiving seasonal influenza vaccine alone. Rates of seroprotection and seroconversion against the three vaccine strains were similar in both groups; however, there was a significant increase in the geometric mean titer ratio for the H3N2 component of seasonal influenza vaccine in the coadministration group. While some vaccine combinations result in immune interference, the coadministration of MVA-NP+M1 alongside seasonal influenza vaccine is shown here to increase some influenza strain-specific antibody responses and boost memory T cells capable of recognizing a range of influenza A subtypes. © The American Society of Gene and Cell Therapy. |
| spellingShingle | Antrobus, R Berthoud, T Mullarkey, C Hoschler, K Coughlan, L Zambon, M Hill, A Gilbert, S Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses |
| title | Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses |
| title_full | Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses |
| title_fullStr | Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses |
| title_full_unstemmed | Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses |
| title_short | Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses |
| title_sort | coadministration of seasonal influenza vaccine and mva np m1 simultaneously achieves potent humoral and cell mediated responses |
| work_keys_str_mv | AT antrobusr coadministrationofseasonalinfluenzavaccineandmvanpm1simultaneouslyachievespotenthumoralandcellmediatedresponses AT berthoudt coadministrationofseasonalinfluenzavaccineandmvanpm1simultaneouslyachievespotenthumoralandcellmediatedresponses AT mullarkeyc coadministrationofseasonalinfluenzavaccineandmvanpm1simultaneouslyachievespotenthumoralandcellmediatedresponses AT hoschlerk coadministrationofseasonalinfluenzavaccineandmvanpm1simultaneouslyachievespotenthumoralandcellmediatedresponses AT coughlanl coadministrationofseasonalinfluenzavaccineandmvanpm1simultaneouslyachievespotenthumoralandcellmediatedresponses AT zambonm coadministrationofseasonalinfluenzavaccineandmvanpm1simultaneouslyachievespotenthumoralandcellmediatedresponses AT hilla coadministrationofseasonalinfluenzavaccineandmvanpm1simultaneouslyachievespotenthumoralandcellmediatedresponses AT gilberts coadministrationofseasonalinfluenzavaccineandmvanpm1simultaneouslyachievespotenthumoralandcellmediatedresponses |